GRFS - Grifols SA ADR logo

GRFS

Grifols SA ADR

Revenue grew 100% of years5Y
Compare GRFS Hold

Grifols develops, produces, and markets plasma-derived medicines and diagnostic solutions, primarily serving hospitals and life-science research sectors. Its offerings include hemoderivatives, diagnostic equipment, clinical nutrition, and healthcare solutions.

โš•๏ธ Healthcare NASDAQ Listed 2006 $ USD
$1,000 invested 5 years ago โ†’$503today

Score Overview

1 Year
Score
Net Growth17.19%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth2.81%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.4
Net Growth139.76%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth50.62%
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth-17.04%
Net Trend50%
Net Income Consistency
Rev Growth83.48%
Rev Trend90%
Revenue Consistency
20 Years
Score6.4
Net Growth9x
Net Trend65%
Net Income Consistency
Rev Growth11x
Rev Trend95%
Revenue Consistency
All Time
Score
Net Growth9x
Net Trend65%
Net Income Consistency
Rev Growth11x
Rev Trend95%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Grifols SA ADR has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 20 years of fundamentals. GRFS does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 7.41โ€”
1 Year2025-09-26
$ 9.69-23.53%
5 Years2021-09-28
$ 14.72-49.68%
10 Years2016-09-28
$ 13.94-46.85%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 7.43B$ 452M$ 529M
2025$ 7.22B$ 386M$ 824M
2024$ 7.21B$ 156M$ 1.00B
2023$ 6.59B$ 42M$ 646M
2022$ 6.06B$ 185M$ 580M
2021$ 4.93B$ 188M$ 2.68B
2020$ 5.34B$ 618M$ 590M
2019$ 5.09B$ 625M$ 2.75B
2018$ 4.48B$ 596M$ 1.03B
2017$ 4.31B$ 662M$ 886M
2016$ 4.04B$ 545M$ 895M
2015$ 3.93B$ 532M$ 1.14B
2014$ 3.35B$ 470M$ 1.07B
2013$ 2.74B$ 345M$ 708M
2012$ 2.62B$ 256M$ 473M
2011$ 1.79B$ 50M$ 357M
2010$ 990M$ 115M$ 252M
2009$ 913M$ 147M$ 257M
2008$ 814M$ 121M$ 13M
2007$ 703M$ 87M$ 12M
IPO2006$ 648M$ 45M$ 33M
GRFS - Grifols SA ADR logo

Grifols SA ADR fundamental performance

Between 2020 and 2025, revenue grew from $ 5.34B to $ 7.22B and net income declined from $ 618M to $ 386M. Revenue increased in every one of those 5 years; net income in 3.

Between 2006 and 2025, revenue grew from $ 648M to $ 7.22B and net income grew from $ 45M to $ 386M. Revenue increased in 95% of the years measured; net income in 65%.

Grifols SA ADR currently holds a 20-year HDB Score of 6.4 out of 10. How the HDB Score is calculated.

Membership

Explore GRFS with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies